Genital Herpes (HSV) Medication Study

The University of Washington is seeking volunteers for an investigational HSV-2 medication trial. The purpose of this clinical trial is to test an investigational HSV-2 medication to determine its safety and effects in the body.

The study will enroll participants who have a history of recurrent genital HSV-2. Participants will be randomized to receive either investigational medicine or placebo. Participants must be willing to stop the use of episodic or suppressive antiviral therapy to treat HSV symptoms for a 42-day period during the study.

The trial will last around 3 months and will involve a minimum of 11 in-person visits. Study visits will involve physical exams and blood draws. As part of the study, participants will also be asked to collect anogenital swabs twice a day for a 28-day period and to complete daily symptom
diaries. At two of the study visits, participants will need to stay at the clinic for 8 hours for repeat blood draws, about once an hour.

Participant Eligibility

To be eligible for the trial you must:
▪ Be 18 – 60 years of age
▪ Have a history of recurrent genital herpes (HSV-2)
▪ Not planning to become pregnant or breastfeed in the near future
▪ Be willing and able to take oral medications

Conditions which would prevent you from participating:
▪ Currently breastfeeding or pregnant
▪ History of serious reactions to medications such as anaphylaxis or skin reactions
▪ Living with HIV, Hepatitis A, B or C

Compensation:
Participants will be compensated up to $2,425 for participating in this study

Clinic Location:
Our clinic is located on the 11th floor of the Ninth and Jefferson Building at Harborview Medical
Center and open Monday through Friday [8:00am to 5pm].

Contact

University of Washington Virology Research Clinic
(206) 520-4340